Who are levo-folinic acid's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Antizol, Cyanokit, Acetadote, multivitamin, Digoxin immune fab, Digoxin Antibodies Fab Fragments.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/levo-folinic-acid.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

levo-folinic acid — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

levo-folinic acid (levo-folinic acid) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antidote. Area: Oncology.

phase 3 Antidote Oncology Small molecule Live · refreshed every 30 min

Target snapshot

levo-folinic acid (levo-folinic acid) — National Cancer Institute, Naples. Levo-folinic acid is a form of folinic acid used to help counteract the toxic effects of methotrexate.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
levo-folinic acid TARGET	levo-folinic acid	National Cancer Institute, Naples	phase 3	Antidote
Antizol	FOMEPIZOLE	Par Pharm Inc	marketed	Antidote [EPC]	Alcohol dehydrogenase	1997-01-01
Cyanokit	HYDROXOCOBALAMIN	Btg Intl	marketed	Antidote		1978-01-01
Acetadote	Acetylcysteine	Bristol-Myers Squibb	marketed	Antidote	Glutathione levels; reactive metabolite of acetaminophen	1963-01-01
multivitamin	multivitamin	New York State Institute for Basic Research	marketed	Antidote [EPC]
Digoxin immune fab	Digoxin immune fab	National Institute on Aging (NIA)	marketed	Antidote; Immunoglobulin fragment	Digoxin (cardiac glycoside)
Digoxin Antibodies Fab Fragments	Digoxin Antibodies Fab Fragments	University of Maryland, Baltimore	marketed	Antidote; Digoxin-specific antibody fragment	Digoxin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-05-21 — Acetadote · 8148356 · Formulation · US
2031-07-21 — Acetadote · 9327028 · Method of Use · US
2032-04-06 — Acetadote · 8722738 · Method of Use · US
2032-05-08 — Acetadote · 8747894 · Formulation · US
2032-05-08 — Acetadote · 9561204 · Method of Use · US
2032-05-08 — Acetadote · 9427421 · Formulation · US

Sponsor landscape (Antidote class)

· 1 drug in this class
Bristol-Myers Squibb · 1 drug in this class
Btg Intl · 1 drug in this class
National Cancer Institute, Naples · 1 drug in this class
Xijing Hospital of Digestive Diseases · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). levo-folinic acid — Competitive Intelligence Brief. https://druglandscape.com/ci/levo-folinic-acid. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab